Misha Movahed-Ezazi

Misha Movahed-Ezazi

Auto-generated profile, based on publicly available information

Misha Movahed-Ezazi

Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health , New York, New York 10016

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Laboratory Investigation
Verified
Journal Article
Closed access
MMMisha Movahed-Ezazi
Misha Movahed-Ezazi
MNMustafa Nasir-Moin
Mustafa Nasir-Moin
CFCamila Fang
Camila Fang
IPIsabella Pizzillo
Isabella Pizzillo
KGKristyn Galbraith
Kristyn Galbraith
MSMatija Snuderl
Matija Snuderl

29 April 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
SBSarra Belakhoua
Sarra Belakhoua
VVVarshini Vasudevaraja
Varshini Vasudevaraja
CSChanel Schroff
Chanel Schroff
KGKristyn Galbraith
Kristyn Galbraith
MMMisha Movahed-Ezazi
Misha Movahed-Ezazi
MSMatija Snuderl
Matija Snuderl
Background: Pituitary neuroendocrine tumors (PitNETs) are the most common intracranial neuroendocrine tumors. PitNETs can be challenging to classify, and current recommendations include a large immunohistochemical panel to differentiate among 14 WHO-recognized categories. Methods: In this study, we analyzed clinical, immunohistochemical, and DNA methylation data of 118 PitNETs to develop a clinicomolecular approach to classifying PitNETs and identifying epigenetic classes. Results: CNS DNA methylation classifier has an excellent performance in recognizing PitNETs and distinguishing the 3 lineages when the calibrated score is ≥ 0.3. Unsupervised DNA methylation analysis separated PitNETs into 2 major clusters. The first was composed of silent gonadotrophs, which form a biologically distinct group of PitNETs characterized by clinical silencing, weak hormonal expression on immunohistochemistry, and simple copy number profile. The second major cluster was composed of corticotrophs and Pit1 lineage PitNETs, which could be further classified using DNA methylation into distinct subclusters that corresponded to clinically functioning and silent tumors and are consistent with transcription factor expression. Analysis of promoter methylation patterns correlated with lineage for corticotrophs and Pit1 lineage subtypes. However, the gonadotrophic genes did not show a distinct promoter methylation pattern in gonadotroph tumors compared to other lineages. Promoter of the NR5A1 gene, which encodes SF1, was hypermethylated across all PitNETs clinical and molecular subtypes including gonadotrophs with strong SF1 protein expression indicating alternative epigenetic regulation. Conclusion: Our findings suggest that classification of PitNETs may benefit from DNA methylation for clinicopathological stratification.

17 October 2020 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
MMMisha Movahed-Ezazi
Misha Movahed-Ezazi
PSPaul J Schwartz
Paul J Schwartz
DZDavid L Zimmerman
David L Zimmerman
XSXianyuan Song
Xianyuan Song

1 January 2024 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
CFCamila S Fang
Camila S Fang
WWWanyi Wang
Wanyi Wang
CSChanel Schroff
Chanel Schroff
MMMisha Movahed-Ezazi
Misha Movahed-Ezazi
VVVarshini Vasudevaraja
Varshini Vasudevaraja
MSMatija Snuderl
Matija Snuderl
In many cancers, specific subtypes are more prevalent in specific racial backgrounds. However, little is known about the racial distribution of specific molecular types of brain tumors. Public data repositories lack data on many brain tumor subtypes as well as diagnostic annotation using the current World Health Organization classification. A better understanding of the prevalence of brain tumors in different racial backgrounds may provide insight into tumor predisposition and development, and improve prevention. We retrospectively analyzed the racial distribution of 1709 primary brain tumors classified by their methylation profiles using clinically validated whole genome DNA methylation. Self-reported race was obtained from medical records. Our cohort included 82% White, 10% Black, and 8% Asian patients with 74% of patients reporting their race. There was a significant difference in the racial distribution of specific types of brain tumors. Blacks were overrepresented in pituitary adenomas (35%, P < .001), with the largest proportion of FSH/LH subtype. Whites were underrepresented at 47% of all pituitary adenoma patients (P < .001). Glioblastoma (GBM) IDH wild-type showed an enrichment of Whites, at 90% (P < .001), and a significantly smaller percentage of Blacks, at 3% (P < .001). Molecularly classified brain tumor groups and subgroups show different distributions among the three main racial backgrounds suggesting the contribution of race to brain tumor development.

18 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJamin Wu
Jamin Wu
SCShih-Chun A. Chu
Shih-Chun A. Chu
JCJang Cho
Jang Cho
MMMisha Movahed-Ezazi
Misha Movahed-Ezazi
KGKristyn Galbraith
Kristyn Galbraith
RRRussell J. H. Ryan
Russell J. H. Ryan
Standard techniques for detecting genomic rearrangements in formalin-fixed paraffin-embedded (FFPE) biopsies have important limitations. We performed FFPE-compatible Hi-C on 44 clinical biopsies comprising large B-cell lymphomas (n=18), plasma cell neoplasms (n=14), and other diverse lymphoid cancers, identifying consistent topological differences between malignant B cell and plasma cell states. Hi-C detected expected oncogene rearrangements at high concordance with fluorescence in-situ hybridization (FISH) and supported enhancer-hijacking in recurrent rearrangements of BCL2 , CCND1 , and MYC , plus unanticipated variants involving homologous loci. Hi-C identified unanticipated non-coding rearrangements involving PD-1 ligand genes and other loci of potential therapeutic relevance, distinguished between functionally divergent classes of BCL6 rearrangements, and provided topological information supporting the interpretation of atypical MYC rearrangements. In biopsies lacking MYC -activating rearrangements, Hi-C revealed differential interactions with functionally-validated disease-specific native MYC locus enhancers. FFPE-compatible Hi-C detects oncogene rearrangements and their topological consequences at genome-wide scale, finding clinically-relevant drivers that are missed by standard approaches.

13 August 2021 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
MMMisha Movahed-Ezazi
Misha Movahed-Ezazi
KSKarin A Skalina
Karin A Skalina
KPKalind Parashar
Kalind Parashar
SMSunil Manjila
Sunil Manjila
AVAlexandre Vdovenko
Alexandre Vdovenko
RCRichard W Cartun
Richard W Cartun